Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line

Journal of Cellular Biochemistry

Volumn 61, Issue 3, 1996, Pages 430-443

  Lengyel, Ernst ^a,b   Gum, Rebecca ^a   Stepp, Evan ^a   Juarez, Jose ^a   Wang, Heng ^a   Boyd, Douglas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

AP 1; c raf; ERK; MAPK; Urokinase type plasminogen activator

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; UROKINASE;

ARTICLE; CANCER CELL CULTURE; ENZYME ANALYSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

BLOTTING, WESTERN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, JUN; HUMANS; MUTAGENESIS; ONCOGENE PROTEINS V-FOS; PROMOTER REGIONS (GENETICS); PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030010553     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N     Document Type: Article

References (63)

1. Andreasen P, Kristensen P, Lund LR, Dano K (1990): Urokinase-type plasminogen activator activator is increased in the involuting ventral prostate of castrated rats. Endocrinology 126:2567-2576.
2. Angel P, Hattori K, Smeal T, Karin M (1988): The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55:875-885.
3. Auble DT, Brinckerhoff CE (1991): The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. Biochemistry 30:4629-4635.
4. Axelrod JH, Reich R, Miskin R (1989): Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH3T3 cells. Mol Cell Biol 9:2133-2141.
5. Bell SM, Connoly DC, Maihle NJ, Degen JL (1993): Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases. Mol Cell Biol 13:5888-5897.
6. Botteri FM, Ballmer-Hofer K, Rajput B, and Nagamine Y (1990): Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J Biol Chem 265:13327-13334.
7. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ (1993): Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Oncogene 8:877-886.
8. Bruder JT, Heidecker G, Rapp UR (1992): Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev 6:545-556.
9. Clayman G, Wang SW, Nicolson GL, El-Naggar A, Mazar A, Henkin J, Blasi F, Goepfert H, Boyd D (1993): Regulation of urokinase-type plasminogen activator expression in squamous cell carcinoma of the oral cavity. Int J Cancer 54:73-80.
10. Coffer P, de Jonge M, Mettouchi A, Binetruy B, Ghysdael J, Kruijer W (1994): junB promoter regulation: ras mediated transactivation by c-ets-1 and c-ets-2. Oncogene 9:911-921.
11. Crews CM, Alessandrini A, Erikson RL (1992): The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478-480.
12. Cubellis M, Wun T, Blasi F (1990): Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9:1079-1085.
13. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P (1995): Heterodimerization of c-jun with ATF-2 and c-fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 11:365-376.
14. de Groot RP, Sasso-Corsi P (1993): Hormonal control of gene expression: multiplicity and versatility of cyclic adenosine 3′ 5′-monophosphate-responsive nuclear regulators. Mol Endocrinology 7:145-153.
15. Degen JL, Estensen RD, Nagamine Y, Reich E (1985): Induction and desensitization of plasminogen activator gene expression by tumor promoters. J Biol Chem 260: 12426-12433.
16. Deng T, Karin M (1995): c-Fos transcriptional activity stimulated by H-ras-activated protein kinase distinct from JNK and ERK. Nature 371:171-175.
17. Dent P, Jelinek T, Morrison DK, Weber MJ, Sturgill TW (1995): Reversal of raf-1 activation by purified and membrane-associated protein phosphatases. Science 268:1902-1906.
18. Derijard B, Raingeaud J, Barrett T, Wu I, Han J, Ulevitch J, Davis RJ (1995): Independent human MAP kinase signal transduction pathways defined by MEK an MKK isoforms. Science 267:682-685.
19. Dignam JD, Lebovitz RM, Roeder RG (1983): Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
20. Domann FE, Levy JP, Birrer MJ, Bowden GT (1994): Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Diff 5:9-16.
21. Ellis V, Behrendt N, Dano K (1991): Plasminogen activation by receptor-bound urokinase. J Biol Chem 266:752-758.
22. Frost JA, Geppert TD, Cobb MH, Feramisco JR (1994): A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-ras, phorbol 12-myristate 13 acetate, and serum. Proc Natl Acad Sci USA 91:3844-3848.
23. tcf by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358: 414-417.
24. Grimaldi G, Di Fiore P, Locatelli EK, Falco J, Blasi F (1986): Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J 5:855-861.
25. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR and Ozols RF (1983): Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43:5379-5389.
26. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle A, Blasi F (1992): A novel complex between the p65 subunit of NF-kB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 11:205-213.
27. Hibi M, Lin A, Minden A, Karin M (1993): Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135-2148.
28. Jelinek T, Catling AD, Reuter CWM, Moodie SA, Wolfman A, Weber MJ (1994): Ras and raf-1 form a signalling complex with MEK-1 but not MEK-2. Mol Cell Biol 14: 8212-8218.
29. Karin M (1994): Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr Opin Cell Biol 6:415-424.
30. Kasai S, Arimura H, Nishida M, Suyama T (1985): Primary structure of single-chain prourokinase. J Biol Chem 260: 12382-12389.
31. Kessler TL, Markus G (1993): Different induction pathways for urokinase (u-PA) in A431 cells by EGF and by the phorbol ester, TPA. Fibrinolysis 7:31-40.
32. Kolch W, Heidecker G, Lloyd P, Rapp UR (1991): Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426-428.
33. Kolesnick R, Golde DW (1994): The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77:325-328.
34. Kyriakis JM, App H, Zhang X, Banerjee P, Brautigan DL, Rapp UR, Avruch J (1992): Raf-1 activates MAP kinase-kinase. Nature 358:417-420.
35. Lengyel E, Stepp E, Boyd D (1995a): Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 270:23007-23012.
36. Lengyel E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M, Boyd D (1995b): Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 11:2639-2648.
37. Liotta L, Goldfarb R, Brundage R, Siegel G, Terranova V, Garbisa S (1981): Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629-4636.
38. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M (1994a): Differential activation of ERK and JNK mitogen-activated protein kinases by raf-1 and MEKK. Science 266:1719-1722.
39. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R, Karin M (1994b): c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 14:6683-6688.
40. Miyajima Y, Nakano R, Morimatsu M (1995): Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol-Rhino-Laryngol 104:678-684.
41. erk-2. J Biol Chem 270:269-273.
42. Nanbu R, Menoud P, Nagamine Y (1995): Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 14:4920-4928.
43. Nerlov C, Rorth P, Blasi F, Johnsen M (1991): Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 6:1583-1593.
44. Nerlov C, De Cesare D, Pergola F, Carracciolo A, Blasi F, Johnsen M, Verde P (1992): A regulatory element that mediates co-operation between a PEA3-AP-1 element and AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11:4573-4582.
45. Nielsen L, Hansen J, Skrivet L, Wilson E, Kaltoft K, Zenthen J, Dano K (1982). Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21:6410-6415.
46. Ossowski L, Reich E (1983): Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611-619.
47. Pankov R, Umezawa A, Maki R, Der C, Hauser CA, Oshima RG (1994): Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway. Proc Natl Acad Sci USA 91:873-877.
48. Rao VN, Reddy SP (1993). Elk-1 proteins are phosphoproteins and activators of mitogen-activated protein kinase. Cancer Res 53:3449-3454.
49. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F (1985): The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res 13:2759-2771.
50. Rorth P, Nerlov C, Blasi F, Johnsen M (1990): Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbolester. Nucleic Acids Res 18:5009-5017.
51. Rossi P, Grimaldi P, Blasi F, Geremia R, Verde P (1990): Follicle-stimulating hormone and cyclic AMP induce transcription from the human urokinase promoter in primary cultures of mouse Sertoli cells. Mol Endocrinol 4:940-946.
52. Salo T, Liotta L, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K (1982): Secretion of basement collagen degrading enzyme and plasminogen activator by transformed cells - Role in metastasis. Int J Cancer 30:669-673.
53. Sappino A, Belin D, Huarte J, Hirschel-Scholz S, Saurat J, Vassalli J (1991): Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88:1073-1079.
54. Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE, Stabel S (1992): Activation of the c-raf protein kinase by protein kinase C phosphorylation. Oncogene 7:2259-2262.
55. Stacey DW, Roudebush M, Day R, Mosser SD, Gibbs JB, Feig LA (1991): Dominant inhibitory ras mutants demonstrate the requirement for ras activity in the action of tyrosine kinase oncogenes. Oncogene 6:2297-2304.
56. Stacey KJ, Fowles LF, Colman MS, Ostrowski MC, Hume DA (1995): Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol Cell Biol 15:3430-3441.
57. Stoppelli MP, Tacchetti C, Cubellis M, Corti A, Hearing V, Cassani G, Appella E, Blasi F (1986): Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45:675-684.
58. Stoppelli P, Verde P, Grimaldi G, Locatelli E, Blasi F (1986): Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J Cell Biol 102:1235-1241.
59. Storm SM, Rapp UR (1993): Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67:201-210.
60. Strickland S, Reich E (1976): Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and parietal endoderm. Cell 9:231-240.
61. Teyssler JR, Henry I, Dozier C, Ferre D, Adnet JJ, Pluot M (1986): Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: Shift of the c-raf 1 locus. J Natl Cancer Inst 77:1187-1195.
62. Verde P, Boast S, Franze A, Robbiati F, Blasi F (1988): An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16:10699-10715.
63. von der Ahe D, Pearson D, Nagamine Y (1990): Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: A role of protein phosphorylation. Nucleic Acids Res 18:1991-1999.